Cargando…
Are multiple sclerosis therapies safe in severe acute respiratory syndrome coronavirus 2 times?
Autores principales: | Ferrara, Francesco, Porta, Raffaele La, Santilli, Priscilla, D'Aiuto, Vilma, Vitiello, Antonio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8025773/ https://www.ncbi.nlm.nih.gov/pubmed/33283779 http://dx.doi.org/10.4103/ijp.IJP_417_20 |
Ejemplares similares
-
Remdesivir and COVID-19
por: Ferrara, Francesco, et al.
Publicado: (2020) -
Clinical Pharmacology Aspects in Patients Treated with TNF Inhibitors During SARS-Cov-2 Pandemic
por: Ferrara, Francesco, et al.
Publicado: (2021) -
Logistics management provides greater efficiency, governance and compliance
por: Ferrara, Francesco, et al.
Publicado: (2021) -
The risks of liver injury in COVID-19 patients and pharmacological management to reduce or prevent the damage induced
por: Vitiello, Antonio, et al.
Publicado: (2021) -
Pharmacological approach for the reduction of inflammatory and prothrombotic hyperactive state in COVID-19 positive patients by acting on complement cascade
por: Vitiello, A., et al.
Publicado: (2021)